Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

BUPROPION HCL

All products: not a benefit

Other products in the same Health Canada class (N06AX) — coverage varies; not interchangeable

  • Duloxetine (Cymbalta): general benefit, Not a benefit
  • Mirtazapine (Remeron RD): general benefit, Not a benefit
  • Trazodone (Desyrel): general benefit, Not a benefit
  • Venlafaxine (Effexor XR): general benefit
  • Vortioxetine (Trintellix): general benefit
  • Desvenlafaxine (Pristiq): not a benefit

17 more in the class list below

Wellbutrin SR · DIN 02237824 · 100mg · tablet

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2008-11-14 — choose a marketed DIN from the same-category list.Discontinued 2008-11-14 · checked 2026-09-19
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2008-11-14 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2008-11-14 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 315
Reason for Use code 315 For the treatment of depression. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Wellbutrin SR · DIN 02237824 Manufacturer: Biovail Pharmaceuticals Canada; listing date 2000-04-17 Health Canada: Cancelled post market since 2008-11-14 · brand WELLBUTRIN SR · ATC N06AX12 BUPROPION · form Tablet (extended-release) · route Oral · ingredients BUPROPION HYDROCHLORIDE 100 MG · company Biovail pharmaceuticals canada division of biovail corporation · schedule Prescription
Check this DIN again · Health Canada product record

Wellbutrin SR: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61183 · Verify on the e-Formulary ↗ (DIN 02237824)

Source record
DIN 02237824: Wellbutrin SR Raw flags: notABenefit=Y, sec3=Y Item: 281604102; group id 453; item number 1130; lccId 00077; manufacturer id BIO Source form: Tab; strength: 100mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02237824 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=61183
Interchangeable products
Odan Bupropion SR · DIN 02275074 · $0.5260
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since 2008-11-14 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (28:16:04 Antidepressants) and how they are covered

Matched class: 28:16:04 Antidepressants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMITRIPTYLINE, CLOMIPRAMINE HCL, FLUVOXAMINE MALEATE, NORTRIPTYLINE, PHENELZINE SULFATE, SERTRALINE HCL, TRANYLCYPROMINE SULFATE, VENLAFAXINE HCL, VORTIOXETINE HYDROBROMIDE Some products covered without a code (check the product listing): CITALOPRAM HYDROBROMIDE, DESIPRAMINE, DOXEPIN HCL, DULOXETINE, ESCITALOPRAM, FLUOXETINE HCL, IMIPRAMINE, MIRTAZAPINE, MOCLOBEMIDE, PAROXETINE HCL, TRAZODONE HYDROCHLORIDE, TRIMIPRAMINE 28:16:04 Antidepressants

DULOXETINE

· 38 products · Listed, not a benefit (2), General benefit (36) · strengths: 30mg, 60mg · DR Cap

MIRTAZAPINE

· 25 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 15mg, 30mg, 45mg · Orally Disintegrating Tab, Tab

TRAZODONE HYDROCHLORIDE

· 17 products · Listed, not a benefit (3), General benefit (14) · strengths: 50mg, 100mg, 150mg · Tab

VENLAFAXINE HCL

· 45 products · General benefit · strengths: 37.5mg, 75mg, 150mg · ER Cap

VORTIOXETINE HYDROBROMIDE

· 6 products · General benefit · strengths: 5mg, 10mg, 20mg · Tab

DESVENLAFAXINE

· 18 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mg, 100mg · ER Tab

VILAZODONE HYDROCHLORIDE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 10mg, 20mg, 40mg · Tab

AMITRIPTYLINE

· 12 products · General benefit · strengths: 10mg, 25mg, 50mg · Tab

CITALOPRAM HYDROBROMIDE

· 51 products · Off-Formulary Interchangeable, not an ODB benefit (9), General benefit (42) · strengths: 10mg, 20mg, 40mg · Tab

CLOMIPRAMINE HCL

· 5 products · General benefit · strengths: 25mg, 50mg, 10mg · Tab

DESIPRAMINE

· 7 products · Listed, not a benefit (4), General benefit (3) · strengths: 25mg, 50mg, 75mg · Tab

DOXEPIN HCL

· 20 products · General benefit (12), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 10mg, 25mg, 50mg, 75mg, 100mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:04 and 12 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 Indications ZYBAN (bupropion hydrochloride) is indicated as smoking cessation treatment in conjunction with behavioural modification; nicotine replacement therapy may be used together with ZYBAN. Prior to a decision to prescribe a non-nicotine treatment including ZYBAN, thorough consideration should be given to the treatment option of nicotine replacement therapy alone. 1.1 Pediatrics Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use (see Potential association with behavioural and emotional changes, including self-harm). 1.2 Geriatrics Geriatrics (≥65 years of age): No overall differences in safety or effectiveness were observed between these subjects and younger subjects, but because geriatric patients are more likely to have decreased renal function, greater sensitivity of some older individuals to bupropion cannot be ruled out (see Renal Impairment and 4 Dosage and Administration). https://pdf.hres.ca/dpd_pm/00080547.PDF PM date: 2025-05-16 Source product: ZYBAN; DIN 02238441; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Free programs for Smoking cessation (Ontario): Ontario Drug Benefit (ODB) Plan coverage of Champix® and Zyban® — coverage of varenicline (Champix®) and bupropion (Zyban®); generic varenicline and bupropion are Limited Use (Reason for Use code 423 for varenicline: 'For smoking-cessation treatment in adults, in conjunction with smoking-cessation counseling', limited to 12 weeks, 168 tablets, per 365 days; code 315 for bupropion) — patients who are seniors (age 65+), in long term-care homes, or those on social assistance (welfare or because of disability) — not stated (toronto.ca, Sep 9, 2026 ↗) Implementing STOP (Smoking Treatment for Ontario Patients) — publicly funded Nicotine Replacement Therapy (NRT) for your patients — residents of Ontario — free (intrepidlab.ca, Sep 9, 2026 ↗) STOP on the Net — free nicotine replacement therapy (NRT) patches and gum/lozenges for 6 weeks of treatment mailed to you within 2 weeks of enrollment — 18 years of age or older and lives within Ontario — free (intrepidlab.ca, Sep 9, 2026 ↗) Smokers' Helpline — quit coach for free, confidential, one-to-one support — patients who want tobacco use cessation counseling/support — free (toronto.ca, Sep 9, 2026 ↗) Pharmacy Smoking Cessation Program — smoking cessation counseling from a pharmacist — eligible ODB recipients — not stated (toronto.ca, Sep 9, 2026 ↗) The Guidebook also includes information on the Pharmacy Smoking Cessation Program for Ontario Drug Benefit recipients who want to quit smoking as part of the Ontario Government’s support to quit smoking. (ontario.ca, Updated August 24, 2023 ↗)

Other review policies

For Wellbutrin SR: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026